Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shire Seizes On Gaucher Opening With EMEA Filing For Velaglucerase

This article was originally published in The Pink Sheet Daily

Executive Summary

Given the shortage of Genzyme's Cerezyme treatment, European regulators decided to grant an accelerated review for Shire's medication.

You may also be interested in...

Genzyme, FDA Warn Of Foreign Particles Found In Some Lots Of Five Drugs

Although the drugs in question all are manufactured or finished and filled at the Allston Landing, Mass., plant, Genzyme says the current difficulty is not related to prior manufacturing problems associated with that facility.

Stronger Together: Pfizer Highlights Newly Combined Oncology Portfolio

The company showcased its expanded cancer drug pipeline two months after completing the acquisition of Seagen last year.

BIO Chair Ted Love On Drug Pricing And Political Pressure

Biopharma veteran Ted Love assured industry that the sector remains fundamentally strong during remarks at the BIO CEO & Investor Conference.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts